Surveillance and medical protocols are in place, but environmental factors for the epidemic reappearing regularly cannot be ruled out.

The report provides a detailed analysis of the current myelodysplastic syndrome marketed drugs and late-stage pipeline drugs.

How fast does a fish disappear? How long does it take to erase all evidence of its life, to turn it into a fillet? What about ...

Three De-suup trainees, a man and two women, have died at the national referral hospital after a Leptospirosis outbreak at a ...

The report provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs. Inside the ARDS Market | How Tech, Awareness, Rising ...

The R/I ratio showed limited accuracy in predicting lung recruitability in ARDS but reliably identified low recruiters.

In the U.S. alone, ARDS affects over 500,000 patients per year, or roughly 10% of all ICU admissions. With no effective pharmacological therapies currently available for ARDS and its high ...

Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN ...

Even with aggressive medical management, 40% of ARDS patients do not survive, and those who do may suffer from long-term complications, including impaired lung function and reduced quality of life.

Patients with acute respiratory distress syndrome faced an accelerated and heightened risk for 90-day mortality between ages 11 and 65, according to results published in American Journal of ...

Dublin, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...